|
JP5173838B2
(ja)
|
2006-02-13 |
2013-04-03 |
アレシア・バイオセラピューティクス・インコーポレーテッド |
骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
|
|
US8168181B2
(en)
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
AU2008230795B2
(en)
|
2007-03-27 |
2014-05-29 |
Bioassets, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
|
PH12012501157A1
(en)
|
2009-12-22 |
2012-10-29 |
Roche Glycart Ag |
Anti-her3 antibodies and uses thereof
|
|
KR101764453B1
(ko)
|
2010-04-09 |
2017-08-02 |
아베오 파마슈티컬즈, 인크. |
항-erbb3 항체
|
|
ME02637B
(me)
|
2010-08-20 |
2017-06-20 |
Novartis Ag |
Antitela za receptor 3 faktora rasta epiderma (her3)
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
WO2012059857A2
(en)
|
2010-11-01 |
2012-05-10 |
Symphogen A/S |
Pan-her antibody composition
|
|
ITRM20100577A1
(it)
|
2010-11-02 |
2012-05-03 |
Takis Srl |
Immunoterapia contro il recettore erbb-3
|
|
US20140134170A1
(en)
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
EP2815765A1
(en)
|
2011-03-15 |
2014-12-24 |
Merrimack Pharmaceuticals, Inc. |
Overcoming resistance to ERBB pathway inhibitors
|
|
MX336197B
(es)
|
2011-04-19 |
2016-01-11 |
Merrimack Pharmaceuticals Inc |
Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
|
|
CA2842860A1
(en)
*
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
|
WO2013033008A2
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
WO2013048883A2
(en)
|
2011-09-30 |
2013-04-04 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
EP2764364B1
(en)
*
|
2011-10-06 |
2021-08-18 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-erbb3 antibodies
|
|
CN108424456B
(zh)
|
2011-11-23 |
2022-04-26 |
医学免疫有限责任公司 |
特异于her3的结合分子及其用途
|
|
EP2788382A2
(en)
*
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
CN108341873B
(zh)
*
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
|
EP2788381A2
(en)
*
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
|
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
|
AU2013293062A1
(en)
|
2012-07-19 |
2014-07-24 |
Alethia Biotherapeutics Inc. |
Anti-Siglec-15 antibodies
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
SG11201506451UA
(en)
|
2013-03-06 |
2015-09-29 |
Merrimack Pharmaceuticals Inc |
Anti-c-met tandem fc bispecific antibodies
|
|
EP2821071A1
(en)
|
2013-07-04 |
2015-01-07 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Compounds for breast cancer treatment
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
US10035847B2
(en)
|
2013-10-02 |
2018-07-31 |
The Rockefeller University |
Amyloid protofibril antibodies and methods of use thereof
|
|
WO2015100459A2
(en)
|
2013-12-27 |
2015-07-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
US10538591B2
(en)
*
|
2014-03-10 |
2020-01-21 |
The Brigham And Women's Hospital, Inc. |
Anti-fibulin-3 antibodies and uses thereof
|
|
TW201622743A
(zh)
*
|
2014-03-19 |
2016-07-01 |
財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 |
免疫原醣肽、包含該醣肽之組合物及其用途
|
|
ES2772817T3
(es)
|
2014-04-10 |
2020-07-08 |
Obi Pharma Inc |
Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
US10526416B2
(en)
|
2014-09-08 |
2020-01-07 |
Yeda Research And Development Co. Ltd. |
Anti-HER3 antibodies and uses of same
|
|
WO2016038610A1
(en)
|
2014-09-08 |
2016-03-17 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
|
|
KR102390359B1
(ko)
*
|
2014-09-29 |
2022-04-22 |
삼성전자주식회사 |
폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
|
|
CN104861068B
(zh)
*
|
2015-01-23 |
2020-11-17 |
中国人民解放军军事科学院军事医学研究院 |
一种全人源抗her3抗体及其治疗相关疾病的用途
|
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
|
AU2016335842A1
(en)
*
|
2015-10-07 |
2018-04-12 |
Obi Pharma, Inc. |
Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
|
|
US20180346571A1
(en)
*
|
2015-11-17 |
2018-12-06 |
Oncomed Pharmaceuticals, Inc. |
Pd-l1-binding agents and uses thereof
|
|
WO2017091615A1
(en)
*
|
2015-11-24 |
2017-06-01 |
Cellerant Therapeutics, Inc. |
Humanized anti-cll-1 antibodies
|
|
KR101746152B1
(ko)
*
|
2015-12-07 |
2017-06-13 |
주식회사 이수앱지스 |
ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
WO2017160990A1
(en)
|
2016-03-15 |
2017-09-21 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
|
|
US11155617B2
(en)
*
|
2016-06-23 |
2021-10-26 |
Jiangsu Hengrui Medicine Co., Ltd. |
LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
|
|
CN106692969B
(zh)
*
|
2016-12-08 |
2021-08-10 |
北海康成（北京）医药科技有限公司 |
抗erbb3抗体及其用途
|
|
US11787858B2
(en)
|
2016-12-22 |
2023-10-17 |
Icahn School Of Medicine At Mount Sinai |
Anti-LILRB3 antibodies and methods of use thereof
|
|
US12667557B2
(en)
|
2017-02-28 |
2026-06-30 |
Daiichi Sankyo Company, Limited |
Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
|
|
TWI771389B
(zh)
|
2017-03-16 |
2022-07-21 |
美商健生生物科技公司 |
抗phf-tau抗體及其用途
|
|
MX2019011252A
(es)
*
|
2017-03-23 |
2020-01-23 |
Univ Pennsylvania |
Anticuerpos anti-c5a y usos de los mismos.
|
|
CN113684275B
(zh)
*
|
2017-06-22 |
2024-02-27 |
北海康成（北京）医药科技有限公司 |
预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
|
|
JP7280238B2
(ja)
*
|
2017-07-17 |
2023-05-23 |
ヤンセン バイオテツク，インコーポレーテツド |
フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
|
|
JP7795860B2
(ja)
|
2017-09-07 |
2026-01-08 |
オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド |
プログラム細胞死タンパク質１に対する抗体
|
|
CN111094339B
(zh)
*
|
2017-10-17 |
2023-01-24 |
江苏恒瑞医药股份有限公司 |
抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
|
|
TW201946654A
(zh)
|
2018-03-05 |
2019-12-16 |
比利時商健生藥品公司 |
抗ＰＨＦ－Ｔａｕ抗體及其用途
|
|
GB201804094D0
(en)
*
|
2018-03-14 |
2018-04-25 |
Ultrahuman Thirteen Ltd |
ERBB3 Binding agents
|
|
MX2020010094A
(es)
|
2018-04-06 |
2021-01-15 |
Dana Farber Cancer Inst Inc |
Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
|
|
WO2020059772A1
(ja)
|
2018-09-20 |
2020-03-26 |
第一三共株式会社 |
抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
|
|
US20220106398A1
(en)
*
|
2019-02-08 |
2022-04-07 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
|
CN113811329B
(zh)
*
|
2019-04-19 |
2025-10-14 |
天科雅生物科技有限公司 |
抗pd-1抗体和其用途
|
|
CN118465272B
(zh)
*
|
2019-12-04 |
2025-08-19 |
珠海泰诺麦博制药股份有限公司 |
抗人巨细胞病毒抗体及其用途
|
|
WO2021167952A2
(en)
*
|
2020-02-20 |
2021-08-26 |
The Feinstein Institutes For Medical Research |
Agonist antibodies against endoglin and uses thereof
|
|
US20240067738A1
(en)
*
|
2020-03-18 |
2024-02-29 |
Elanco Us Inc. |
Anti-il4 receptor antibodies for veterinary use
|
|
TW202227486A
(zh)
*
|
2021-01-04 |
2022-07-16 |
大陸商上海翰森生物醫藥科技有限公司 |
一種抗erbb3受體的抗體或其抗原結合片段及其醫藥用途
|
|
WO2023147470A2
(en)
|
2022-01-28 |
2023-08-03 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
CN114940714B
(zh)
*
|
2022-05-20 |
2023-06-16 |
湖南师范大学 |
肝癌标志物soat1单克隆抗体制备及其应用
|
|
EP4536278A4
(en)
|
2022-06-07 |
2026-08-12 |
Actinium Pharmaceuticals Inc |
CHELETARIANS AND BIFUNCTIONAL CONJUGATES
|
|
CN115109161B
(zh)
*
|
2022-06-28 |
2023-08-11 |
广东赛尔生物科技有限公司 |
含有间充质干细胞的减肥药物组合物
|
|
CN115806619B
(zh)
*
|
2022-10-09 |
2026-08-04 |
苏州市立医院 |
一种单克隆抗体及其用途
|
|
EP4637821A1
(en)
*
|
2022-12-23 |
2025-10-29 |
Actinium Pharmaceuticals, Inc. |
Her3 radioimmunotherapy for the treatment of solid cancers
|
|
JPWO2024248123A1
(cg-RX-API-DMAC10.html)
|
2023-06-02 |
2024-12-05 |
|
|
|
AU2024415931A1
(en)
|
2023-12-27 |
2026-07-16 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
Multi-specific antibody targeting her3 and trop2 and conjugate thereof
|
|
CN118005795B
(zh)
*
|
2024-04-09 |
2024-06-28 |
天津旷博同生生物技术有限公司 |
一种抗人cd64抗体及应用
|